Recurrent Glioblastoma Multiforme

Bevacizumab for recurrent glioblastoma multiforme

Reoperation for Recurrent Glioblastoma Multiforme.

The role of reoperation for glioblastoma multiforme (GBM) recurrence is currently unknown. However, multiple studies have indicated that survival and quality of life are improved with a repeat operation at the time of disease recurrence. Prognosis is likely interdependent on several factors, including age, functional status, initial resection status, disease location, and surgical efficacy. How...

'Recurrent' glioblastoma multiforme, when should we reoperate?

The surgical management of recurrent glioblastoma multiforme is controversial. Recent publications suggest that re-operation provides 3-5 months median survival, without significant increases in morbidity or mortality. Age (< or =50 years, although older patients may also benefit) and performance status (Karnofsky performance score > or =60-70) are the most important factors. Re-resection not o...

PCV chemotherapy for recurrent glioblastoma multiforme.

The authors evaluated response, time to progression (TTP), survival, prognostic factors, and toxicity in 63 patients with a recurrent glioblastoma multiforme treated with procarbazine, lomustine, and vincristine (PCV) chemotherapy. Complete and partial response was observed in two (3%) and five patients (8%). In 16 patients (25%), stable disease was observed. Median TTP and survival were 13 and...

Caelyx in patients with recurrent glioblastoma multiforme

Temozolomide has established activity in the treatment of recurrent glioblastoma multiforme (GBM). Caelyx (liposomal doxorubicin) has established activity in a broad range of tumors but has not been extensively evaluated in the treatment of GBM. Phase 1 data suggest that temozolomide and Caelyx can be combined safely at full dose. In this phase 2 study, combination temozolomide (200 mg/m orally...